Phase 3 Readout~month

Phase 3 Topline: A Phase 2/3, Randomized Study of INBRX-106 Combined With Pembrolizumab Versus Pembrolizumab as First

Indication
Head and Neck Squamous Cell Carcinoma (HNSCC)

Other upcoming events for INBX

Patent ExpiryPatent/Exclusivity Expiry: KHAPZORY
Patent ExpiryPatent/Exclusivity Expiry: VYKOURA

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Phase 2/3, Randomized Study of INBRX-106 Combined With Pembrolizumab Versus Pembrolizumab as First — INBX Phase 3 Readout | BioSniper